Sabitlenmiş Tweet

🚀 R&D Announcement: Relieva IPT Begins Phase 1
Relieva has officially commenced its R&D evaluation stage ahead of the Q1 2026 Roadmap.
Our first proprietary medical cannabis strain under review is a CBG(+) dominant variation, with preliminary analysis showing an exceptional 28% CBGA, one of the highest globally recorded. Most peer strains range only from 8%–22%.
This positions RLV as a major contender in high-value cannabinoid IP and future commercialization potential.
More updates coming soon.
and keep an eye on @BioProtocol

English




















